Wave Life Sciences reported positive proof of concept for obesity candidate WVE-007 in Phase I, with fat loss and preservation of muscle mass. The company is preparing a pivotal Phase II trial for WVE...
Source LinkWave Life Sciences reported positive proof of concept for obesity candidate WVE-007 in Phase I, with fat loss and preservation of muscle mass. The company is preparing a pivotal Phase II trial for WVE...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.